The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG).
 
Sebastian Stasik
No Relationships to Disclose
 
Christian Thiede
Employment - Agendix
Leadership - Agendix
Stock and Other Ownership Interests - Agendix
Honoraria - GWT GmbH; Novartis
Consulting or Advisory Role - Astellas Pharma; Novartis
Speakers' Bureau - Jazz Pharmaceuticals; Novartis
Research Funding - Bayer Schering Pharma (Inst)
 
Sarah Albus
No Relationships to Disclose
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - SERVIER
 
Lutz Jacobasch
Consulting or Advisory Role - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Pfizer (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Abbvie; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Ipsen; Sanofi
 
Ralf Hofheinz
No Relationships to Disclose
 
Lena-Christin Conradi
No Relationships to Disclose
 
Ruediger Liersch
No Relationships to Disclose
 
Anke Kroecher
No Relationships to Disclose
 
Uwe Martens
Stock and Other Ownership Interests - Lilly; Novo Nordisk
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Guardant Health; MSD Oncology; Roche
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Lilly; Pierre Fabre
 
Lydia Reinhardt
No Relationships to Disclose
 
Lukas Weiss
Stock and Other Ownership Interests - Guardant Health
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Deciphera; Merck Serono; MSD; Novocure; Pierre Fabre; Servier/Pfizer; Takeda
Consulting or Advisory Role - Amgen; Amgen; Astellas Pharma; BeiGene; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Novocure; Pierre Fabre; Roche; Takeda
Research Funding - SERVIER (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Janssen Oncology; Merck Serono; Pierre Fabre; Roche; SERVIER
 
Anke Reinacher-Schick
Honoraria - MCI Group; MSD; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Aurikamed; Boehringer Ingelheim; Daiichi Sankyo; MCI Deutschland; Pierre Fabre; Roche; Servier
Research Funding - AIO-Studien (Inst); BioNTech (Inst); Genentech (Inst); Georg-August-Universität Göttingen (UMG) (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MCI Deutschland; MSD; Pierre Fabre; Roche
 
Daniela Aust
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
Consulting or Advisory Role - Incyte Japan; MSD Oncology; SERVIER
Travel, Accommodations, Expenses - Sysmex
 
Andrea Tannapfel
No Relationships to Disclose
 
Gunnar Folprecht
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daichi; Exact Sciences; GlaxoSmithKline; Incyte; Janssen; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Pierre Fabre; Roche/Genentech; SERVIER; Takeda
Research Funding - Merck KGaA (Inst)